RT Journal Article SR Electronic T1 Update on pharmacology of antiplatelets, anticoagulants, and thrombolytics JF Neurology JO Neurology FD Lippincott Williams & Wilkins SP S68 OP S76 DO 10.1212/WNL.0b013e3182695871 VO 79 IS 13 Supplement 1 A1 Cheng-Ching, Esteban A1 Samaniego, Edgar A. A1 Naravetla, Bharath Reddy A1 Zaidat, Osama O. A1 Hussain, Muhammad Shazam YR 2012 UL http://n.neurology.org/content/79/13_Supplement_1/S68.abstract AB Understanding of the pharmacology of thrombolytics, anticoagulants, and antiplatelets is critical to performing safe and effective endovascular therapy for acute ischemic therapy. This is a basic review of the clinical pharmacologic data on the anticoagulants, antiplatelets, and fibrinolytic agents most commonly used in the treatment of stroke and in the neurointerventional suite. CYP=cytochrome P450; FDA=US Food and Drug Administration; HIT=heparin-induced thrombocytopenia; LMWH=low-molecular-weight heparin; Pro-UK=prourokinase; rtPA=recombinant tissue plasminogen activator; tPA=tissue plasminogen activator; UFH=unfractionated heparin; VTE=venous thromboembolism